What is the BiotechSign catalyst score for XENE?

XENE currently has a BiotechSign catalyst score of 78/100 and grade B. Scores combine FDA, clinical trial, insider, dilution, sentiment, short interest, and convergence signals.

What signals does BiotechSign track for XENE?

BiotechSign tracks 0 active signals for XENE, including 0 PDUFA signals, 0 insider buying signals, and 0 clinical trial signals when available.

When was the XENE catalyst page updated?

This XENE page was refreshed from BiotechSign data on 2026-07-19.

You have used your free lookups for today

Upgrade to BiotechSign Pro for unlimited company access, full signal history, watchlist alerts, and 125+ PDUFA dates.

Upgrade to Pro →← Back to screener

← Back to Screener

XENE — Xenon Pharmaceuticals

Xenon Pharmaceuticals

Ion Channel CNSScore: 78/100Full Profile

What is the current XENE catalyst setup?

XENE is tracked by BiotechSign with a current catalyst score of 78/100 and grade B. The page summarizes 0 active signals, including 0 PDUFA, 0 insider buying, and 0 clinical trial signals, with data refreshed on 2026-07-19.

Company SnapshotUpdated 2026-07-19

As of 2026-07-19, Xenon Pharmaceuticals (XENE) has a BiotechSign Catalyst Score of 78/100, rated B. The company has 0 active signals tracked by BiotechSign. BiotechSign scores combine FDA pipeline data, clinical trial activity, SEC insider filings, dilution risk, and sentiment analysis into a single catalyst grade.

This data is for informational purposes only and does not constitute financial or medical advice. Biotech and pharmaceutical stocks carry extreme risk, including binary FDA outcomes that can result in total loss. Always conduct your own due diligence. Source: BiotechSigns (biotechsign.com).

Analyst Summary

Verified 2026-04-11

Xenon Pharmaceuticals (XENE) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov^[3], including 8 Phase 3^[1], 1 Phase 2^[2].

Trial NCT05716100^[4] evaluates XEN1101 in Focal Onset Seizures with a target enrollment of 360 participants. Trial NCT07172516^[5] evaluates Azetukalner in Bipolar Disorder with a target enrollment of 400 participants. Trial NCT06775379^[6] evaluates Azetukalner in Major Depressive Disorder with a target enrollment of 450 participants.

XENE has 3 Form 4 insider filings recorded at the SEC in the past 30 days^[7].

Sources

ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov (2026-04-11) ↗
ClinicalTrials.gov · NCT05716100 (2026-03-12) ↗
ClinicalTrials.gov · NCT07172516 (2026-04-01) ↗
ClinicalTrials.gov · NCT06775379 (2025-10-22) ↗
SEC EDGAR · 0001582313 (2026-04-11) ↗

Not financial advice. BiotechSign scores are for informational purposes only and do not constitute investment recommendations. Always do your own due diligence before making investment decisions.